Phaseline

Targets › GLRB

GLRB (Glycine receptor subunit beta): drug programs, companies and trials

5 programs from 5 companies in 13 trials: 7 Phase 4, 5 Phase 3, 1 Phase 2; Cardiovascular, Oncology, Neurology; next expected readout Nov 2026.

Subunit of heteromeric glycine-gated chloride channels. Plays an important role in the down-regulation of neuronal excitability. (UniProt, P48167)

Open in Phaseline: the race on GLRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kaohsiung Medical University Chung-Ho Memorial HospitalSevoflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Lung Cancer; Hepatocellular Carcinoma; Ovarian CancerNov 2026
Medical University of ViennaDesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Postoperative DeliriumDec 2027
Georgia TsaousiDesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Brain Edema Caused by Drugs–
Xijing Hospitaldesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 3Cardiac SurgeryDec 2028
Sedana MedicalIsoflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 3Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium …–

Conditions

Lung Cancer (1) Hepatocellular Carcinoma (1) Ovarian Cancer (1) Postoperative Delirium (1) Cardiac Surgery (1) Brain Edema Caused by Drugs (1) Post-Intensive Care Syndrome (1) Diabete Mellitus (1) Sedation (1) Prevention of Delirium (1) Intensive Care Units, Pediatric (1) Covid19 (1)

Modalities

small molecule (5)

Companies

Kaohsiung Medical University Chung-Ho Memorial Hospital (1) Medical University of Vienna (1) Xijing Hospital (1) Georgia Tsaousi (1) Sedana Medical (1)

Related targets

GLRA1 (5) GABRA1 (5) GABRB2 (5) GABRG2 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.